About: Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 25 June 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2013 (ast) наукова стаття, опублікована в червні 2013 (uk) scientific article published on 25 June 2013 (en) مقالة علمية نشرت في 25 يونيو 2013 (ar)
publication date	wds:Q37251132-F07DEA9F-06D0-46C8-97DD-8F90137D8BE7
publication date	2013-06-25 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37251132-96DCF0C9-316F-498E-970E-1F31DB3A2A1D
language of work or name	English
cites work	wds:Q37251132-02D1FDCC-9197-4E61-84EF-9CC37F8A0BD1 wds:Q37251132-0424422B-2E8B-4977-B894-F4E2D4937D4D wds:Q37251132-0F5E05CE-3E79-415C-BF35-47383D062E24 wds:Q37251132-23EE7DFF-45FF-4F1E-A60D-48B354E8A0F0 wds:Q37251132-24DE253F-0055-4418-BB1C-BE345737BDB2 wds:Q37251132-29C59F8F-B910-416D-931B-FA82074439B2 wds:Q37251132-3038473E-0E1C-45EA-9EBF-FA6ADA71A50F wds:Q37251132-3C5B85F5-3680-41B4-8C93-064C43FE5655 wds:Q37251132-3C67D639-4EDE-4E14-8F22-7B49D6E61B55 wds:Q37251132-453BFB2C-89A2-4899-8A48-66DF5ACB8A83 wds:Q37251132-490BED8C-4721-4F1B-802A-1AB15DBEAC97 wds:Q37251132-598D4A52-354B-4680-B80D-18848C4B60B8 wds:Q37251132-696E6990-D322-41D6-A66B-4F4F50A3FA01 wds:Q37251132-6BDB0A31-90D1-46E1-81FE-6B2452A2DC43 wds:Q37251132-6D6ABB02-5A0B-4403-9F44-D5D79E8E08F2 wds:Q37251132-6ED26E25-95BE-49DE-B7E5-0C35AE22C8CC wds:Q37251132-7624134A-6DFF-416A-8E69-5D726333B0DA wds:Q37251132-795734A1-622E-4125-96E5-490827CFE72D wds:Q37251132-7B137211-6C1B-4079-93BC-932735ABB163 wds:Q37251132-7F81C90E-459E-4323-BF71-816D9E52BE11 wds:Q37251132-8F29C103-07A3-4292-9A71-3043C9661F55 wds:Q37251132-8F8F3D7E-8F17-4032-82AE-573F9D243016 wds:Q37251132-97E64A4B-6EB5-484A-9649-A877FAC52434 wds:Q37251132-B57EF5EF-C5A7-40D4-8204-7E71E6114438 wds:Q37251132-C216F758-B129-4694-BAC2-0A4B6D1AE52E wds:Q37251132-C30CD39E-FEF5-4F96-B7A2-7901D303F88E wds:Q37251132-C3CD898E-58C7-429A-BFA1-87080BBA4D54 wds:Q37251132-CC4E3F8D-F46F-4069-BD95-E9929CDBDD4A wds:Q37251132-E35ABCE8-0D9E-41DD-94E1-8A15ABEA99E3
cites work	Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. The T1D Exchange clinic registry Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group Diagnosis and classification of diabetes mellitus Standards of medical care in diabetes--2011. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus Immune therapy and β-cell death in type 1 diabetes Insulin secretion in type 1 diabetes Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial GAD treatment and insulin secretion in recent-onset type 1 diabetes GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. IAPP boosts islet macrophage IL-1 in type 2 diabetes Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study Residual Beta-cell Function and Its Metabolic Consequences Otelixizumab in the treatment of type 1 diabetes mellitus
author name string	wds:Q37251132-847281DD-45B9-4365-A298-6794852C7590 wds:Q37251132-86061166-A7B3-400E-BCAD-4CE70E04EC6E wds:Q37251132-90C8F764-C1E0-47B9-83B3-FC14EE91B48C wds:Q37251132-ADF63BCD-7837-4038-8DFF-E13FED06E917 wds:Q37251132-B231AA85-5725-48DA-9967-24056E249C29 wds:Q37251132-B61A874D-6B73-4E8F-8F7B-7B68B35D4605 wds:Q37251132-CB920D6D-BF75-4BA6-A410-549AD8C675A6 wds:Q37251132-E4572267-2568-45DD-8EA7-6719BF95C9EF wds:Q37251132-F864383C-0B63-43A4-BDD0-882642D270AC
author name string	Ezio Bonvini Kathryn E Stein Scott Koenig Syd Johnson William Hagopian Nicole Sherry Anastasia G Daifotis David Carlin Protégé Trial Investigators
rdfs:label	Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial (en) Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial (nl) Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial (ast)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software